Publications

Journal Article Review Epublish

PubMed: 40533746 DOI: 10.1186/s12951-025-03528-2

Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges.

J Nanobiotechnology 23(1):453

Authors: Nima Sanadgol, Mohsen Abedi, Masoud Hashemzaei, Zahra Kamran, Roghayeh Khalseh, Cordian Beyer, Clara Voelz

Affiliations

  • Institute of Neuroanatomy, RWTH University Hospital Aachen, Aachen, Germany.
  • Department of Advanced Technologies, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Medicine, Isfahan University of Medical Sciences, Esfahān, Iran.
  • Institute of Neuroanatomy, RWTH University Hospital Aachen, Aachen, Germany.
  • Hannover Medical School, Institute of Functional and Applied Anatomy, Hannover, Germany.

Abstract

Recent advancements in gene expression modulation and RNA delivery systems have underscored the immense potential of nucleic acid-based therapies (NA-BTs) in biological research. However, the blood-brain barrier (BBB), a crucial regulatory structure that safeguards brain function, presents a significant obstacle to the delivery of drugs to glial cells and neurons. The BBB tightly regulates the movement of substances from the bloodstream into the brain, permitting only small molecules to pass through. This selective permeability poses a significant challenge for effective therapeutic delivery, especially in the case of NA-BTs. Extracellular vesicles, particularly exosomes, are recognized as valuable reservoirs of potential biomarkers and therapeutic targets. They are also gaining significant attention as innovative drug and nucleic acid delivery (NAD) carriers. Their unique ability to safeguard and transport genetic material, inherent biocompatibility, and capacity to traverse physiological barriers highlight their potential as drug carriers. This review provides a comprehensive overview of current strategies to enhance NAD to the brain, focusing on the emerging potential of exosomes as biocompatible and efficient nanocarriers. It synthesizes recent advances in the use of exosomes for NA-BTs in neurological disorders, comparing their advantages with those of conventional nanodelivery systems and cell-based therapies. Additionally, the review highlights innovative exosome engineering approaches to improve brain-targeted delivery, addresses key methodological limitations such as variability in cargo content, and proposes solutions to enhance standardization and safety. Collectively, these insights highlight the translational potential of exosomes and offer a novel perspective on bridging the gap between fundamental research and clinical application.

MeSH

Cells, Genes, Blood, Pharmaceutical Preparations, Brain, Exosomes, Nucleic Acids, Research, Therapeutics